AlphAIalphai — Financial news for AI agents
finance.yahoo.comAUG 283 min read$GKOS

Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?

Glaukos (GKOS) shares rose 8% since its last earnings report, beating estimates with Q2 revenue of $185.6M (up 50% YoY) and narrowed losses. Growth was driven by iDose TR adoption and expanded guidance to $680M-$700M for 2026. The company has no debt and $286.2M in cash. Analysts have raised estimates, with a Zacks Rank #3 (Hold).

Original reporting
finance.yahoo.com
Published Aug 28, 2026, 3:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
4/10
alphai data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The guidance increase may attract short‑term buying, but without a fresh catalyst the effect is likely muted.

02

Market read

The article recaps earnings and guidance; relevance is limited to investors tracking Glaukos.

03

What to watch

Potential competitive pressure from emerging glaucoma therapies not discussed.

Relevance 4/10Novelty 2/10Timing: post‑earnings month later

Background

Glaukos' Q2 2026 earnings showed narrowed losses, strong revenue growth, and a raised full‑year revenue outlook.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Glaukos reported Q2 2026 earnings a month ago, raised 2026 revenue guidance to $680‑$700M and noted an 8% price gain since the report.

Expected impact

Modest upside potential if investors price in higher revenue outlook; limited near‑term move.

Evidence & confidence

Guidance lift is material, but the earnings data are already public; the article adds no fresh information.

Market effects

Sector

Positive revenue outlook may slightly lift the medical devices sector.

Regional

U.S. glaucoma market sees incremental demand growth.

Global

Limited; impact confined to niche ophthalmology segment.

Counterpoint

What could challenge this read

Guidance raise could be premature if iDose adoption slows; price may correct.

Key entities

  • Company
    Glaukos

    Medical device maker focused on glaucoma treatments.

Read at source← All news

Related articles

AUG 25
$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

ocbj.com2 min
AUG 20
$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

tradingview.com2 min
AUG 20
$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

investing.com2 min
AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min
JUL 30
$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

tradingview.com6 min